TY  - GEN
AU  - Lichtenauer,Michael
AU  - Lichtenauer,Michael
TI  - Novel Biomarkers for Heart Disease
SN  - books978-3-03943-884-6
PY  - 2020///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - diet quality
KW  - ceramides
KW  - obesity
KW  - cardiovascular risk
KW  - healthy eating index
KW  - carbohydrate antigen-125
KW  - heart failure
KW  - inflammatory marker
KW  - older women
KW  - biomarker
KW  - cardiometabolic disease
KW  - epicardial adipose tissue
KW  - epicardial fat
KW  - epicardial fat volume
KW  - microRNA
KW  - thyroid-stimulating hormone
KW  - cardiometabolic risks
KW  - metabolic syndrome
KW  - hypertension
KW  - very low-density lipoprotein
KW  - STIM1
KW  - SOCE
KW  - atrial myopathy
KW  - atrial fibrillation
KW  - ejection fraction
KW  - soluble urokinase-type plasminogen activator receptor (suPAR)
KW  - growth differentiation factor 15 (GDF-15)
KW  - heart-type fatty acid-binding protein (H-FABP)
KW  - soluble suppression of tumorigenicity 2 (sST2)
KW  - acute myocardial infarction
KW  - biomarkers
KW  - catestatin
KW  - coronary artery disease
KW  - heart failure decompensation
KW  - left ventricular ejection fraction
KW  - troponin
KW  - NT-proBNP
KW  - NYHA functional class
KW  - GDF-15
KW  - cardiovascular surgery
KW  - operative risk
KW  - muscle wasting
KW  - sarcopenia
KW  - renal dysfunction
KW  - chronic kidney disease
KW  - aortic disease
KW  - aneurysm
KW  - miRNA
KW  - TGF-β pathway
KW  - KLF4
KW  - synthetic phenotype
KW  - aortic regurgitation
KW  - echocardiography
KW  - magnetic resonance imaging
KW  - vena contracta area
KW  - longitudinal strain
KW  - T1 mapping
KW  - GDF8
KW  - myostatin
KW  - AMI
KW  - ceruloplasmin
KW  - H-FABP
KW  - heart-type fatty acid-binding protein
KW  - FABP3
KW  - fatty acid-binding protein 3
KW  - HF
KW  - cardiac biomarkers
KW  - cardiac magnetic resonance imaging
KW  - left ventricular systolic function
KW  - magnetic resonance spectroscopy
KW  - myocardial triglyceride content
KW  - cell adhesion molecule
KW  - repeated measurements
KW  - pregnancy-associated plasma protein-A
KW  - cohort studies
KW  - cardiovascular diseases
KW  - mitochondrial dysfunction
KW  - circulating cells
KW  - PBMCS
KW  - platelets
KW  - oxidative stress
KW  - reactive oxygen species (ROS)
KW  - mitochondrial DNA (mtDNA)
KW  - herat failure
KW  - liver-type fatty-acid-binding protein
KW  - long-term outcomes
KW  - cardiac intensive care units
KW  - acute kidney injury
KW  - myocardial infarction
KW  - STEMI
KW  - cardiovascular events
KW  - cardiovascular death
KW  - risk stratification
KW  - sST2
KW  - Pentraxin-3
KW  - sudden cardiac death
KW  - ventricular arrhythmia
KW  - ventricular tachycardia
KW  - chronic heart failure
KW  - saliva
KW  - salivary biomarkers
KW  - CKD
KW  - CVD
KW  - PPCI
KW  - left ventricular adverse remodelling
KW  - circulating miRNAs
KW  - NAFLD
KW  - Framingham risk score
KW  - risk prediction
KW  - secondary prevention
KW  - primary prevention
KW  - NAFLD fibrosis score
KW  - HFpEF
KW  - HFrEF
KW  - suPAR
KW  - n/a
N1  - Open Access
N2  - Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers
UR  - https://mdpi.com/books/pdfview/book/3255
UR  - https://directory.doabooks.org/handle/20.500.12854/69451
ER  -